This website uses cookies
Read our Privacy policy and Terms of use for more information.
All Posts
/
May 25, 2026
Plus: Genentech's $125,000 grants raise influence concerns, a new kidney cancer combination approved in China, and Gilead renews its WHO leishmaniasis pact
May 18, 2026
Plus: blocking GPNMB to slow Parkinson's, Vyvgart's label opens to all gMG serotypes, and Roche buys PathAI for $1.05B
May 8, 2026
Plus: AstraZeneca restarts its £300M UK investment, the first Chinese-made insulin biosimilar clears the FDA, and Lilly's $2.25B gene-writing alliance
May 1, 2026
Plus: the metabolic wall blocking CAR-T in solid tumours, Coultreon's $125M raise, and Lilly's $2.25B bet on AI-authored gene writing
Apr 24, 2026
Plus: GATA1 as a persistent target in Down syndrome leukaemia, a wave of FDA sterility warning letters, and Roche's brutal Q1
Apr 17, 2026
Plus: engineered dendritic cells that protect the failing heart, Avalyn's IPO bid for inhaled fibrosis drugs, and Takeda walks away from mRNA
Apr 10, 2026
Plus: the single gene mutation that blurs decision-making, Vertex's $15M Hypercon licence, and the US-UK deal giving British pharma a head start
Apr 3, 2026
Plus: Blackstone's record $6.3B life sciences fund, the FDA and EMA's new pact on AI, and Sun Pharma slides on tariff threats
Mar 27, 2026
Plus: Excalipoint's $68.7M seed round, Opdivo's new Hodgkin lymphoma approval, and the GLP-1 price war reshaping how Americans buy drugs
